Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Conditions: Endometrial Cancer; Cervical Cancer; Ovarian Cancer; Urothelial Carcinoma; Biliary Tract Cancer Interventions: Drug: BL-M07D1 Sponsors: SystImmune Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2024 Category: Research Source Type: clinical trials
Exercise for Improving Radiotherapy Efficacy in Rectal Cancer
Conditions: Locally Advanced Rectal Carcinoma Interventions: Other: Supervised Vigorous intensity aerobic interval exercise Sponsors: University of Hull; Hull University Teaching Hospitals NHS Trust Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2024 Category: Research Source Type: clinical trials
Phase Ib/II Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC
Conditions: Hepatocellular Carcinoma Interventions: Drug: Valemetostat; Drug: Atezolizumab; Drug: Bevacizumab Sponsors: University of Alabama at Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2024 Category: Research Source Type: clinical trials
Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer
Conditions: Recurrent Ovarian Carcinoma Interventions: Procedure: Carboplatin or cisplatin; Drug: Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar; Drug: Bevacizumab or biosimilar; Procedure: Cytoreductive surgery Sponsors: The University of Hong Kong Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2024 Category: Research Source Type: clinical trials
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Primary Cytoreductive Surgery
Conditions: Ovarian Cancer; Fallopian Tube Carcinoma; Ovarian Carcinoma; Peritoneal Carcinoma; Ovarian Cancer Stage IIIC; Fallopian Tube Cancer Stage IIIC; Ovarian Cancer Stage IV; Fallopian Tube Cancer Stage IV; Fallopian Tube Cancer; Peritoneal Cancer Interventions: Biological: Acute Normovolemic Hemodilution/ANH Sponsors: Memorial Sloan Kettering Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials
Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy
Conditions: Malignant Neoplasm of Bladder; Muscle Invasive Bladder Carcinoma Interventions: Drug: Neoadjuvant Chemotherapy; Procedure: Partial cystectomy with Extended pelvic lymph node dissection; Drug: Adjuvant systemic therapy Sponsors: Case Comprehensive Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials
Comparison of Outcomes of Multiple Platforms for Assisted Robotic-Kidney (COMPAR-K)
Conditions: Renal Carcinoma Interventions: Device: DaVinci RAPN; Device: Hugo RAS RAPN; Device: Versius ® RAPN Sponsors: Azienda Ospedaliera Universitaria Integrata Verona Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
Conditions: Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8 Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Other: Gallium Ga 68 Gozetotide; Drug: Lutetium Lu 177 Vipivotide Tetraxetan; Procedure: Positron Emission Tomography; Other: Questionnaire Administration; Procedure: Single Photon Emission Computed Tomography Sponsors: Jonsson Comprehensive Cancer Center; Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 1, 2024 Category: Research Source Type: clinical trials
Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Tissues From Egyptian Male Patients and Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in Bladder Cancer.
Conditions: Microbiota in Patients With Urinary Bladder Carcinoma in Urine and Cancer Tissues Sponsors: Theodor Bilharz Research Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 1, 2024 Category: Research Source Type: clinical trials
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Conditions: Extensive Stage Lung Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8 Interventions: Biological: Atezolizumab; Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Biological: Durvalumab; Procedure: Echocardiography; Drug: Iadademstat; Procedure: Magnetic Resonance Imaging; Procedure: Multigated Acquisition Scan Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 1, 2024 Category: Research Source Type: clinical trials
Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma
Conditions: Cutaneous Squamous Cell Carcinoma Interventions: Drug: Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination Sponsors: Melanoma Institute Australia; Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 1, 2024 Category: Research Source Type: clinical trials
Heavy Strength Training in Head and Neck Cancer Survivors
Conditions: Head and Neck Neoplasms; Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Head and Neck Carcinoma Interventions: Other: Experimental Sponsors: University of Alberta Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 1, 2024 Category: Research Source Type: clinical trials
Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma Interventions: Procedure: TOMOX-HAIC; Drug: Sintilimab; Drug: Bevacizumab Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Conditions: Neoplasms; Non-small-cell Lung Cancer; Melanoma; Squamous Cell Carcinoma of the Head and Neck; Renal Cell Carcinoma; Urothelial Carcinoma; Colorectal Carcinoma; Ovarian Carcinoma Interventions: Drug: PF-07820435; Biological: Sasanlimab Sponsors: Pfizer Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
Barriers to Cervical Cancer Screening
Conditions: Cervical Carcinoma Interventions: Other: Non-Interventional Study Sponsors: Mayo Clinic Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
